NorwayNorway

Apim Therapeutics gets new funding

05.04.2011

Trondheim – Norway-based APIM Therapeutics AS has received a follow-up investment from Sarsia Seed, one of its previous investors. APIM focusses on novel drug candidates that potentiate the action of current chemo­therapeutics to treat cancers. The company’s lead candidate ATX-101 targets the Proliferating Cell Nuclear Antigen (PCNA), which seems to be involved in the regulation of cellular responses to DNA damage and stress. ATX-101 showed potential activity as a single agent in blood cancer and solid tumours. The six-digit financing tranche is earmarked for use in the acceleration of the development of ATX-101. According to APIM-CEO Konstantinos Alevizopoulos, the substance could potentially be used to treat several types of cancer.

NorwayNorway

05.04.2011

Oslo – Norwegian Algeta ASA has entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform Under the terms of the agreement, Genzyme will provide access to a novel tumour-targeting antibody,...

NorwayNorway

04.11.2010

Oslo – Norwegian diagnostic specialist DiaGenic ASA has raised NOK70m (EUR 8.5m) through the sale of 140 million shares at NOK0.50 per share in a private placement to new and existing investors. DnB NOR Markets acted as manager...

NorwayNorway

03.11.2010

Oslo – The Oslo Cancer Cluster and the Shanghai Institute of Materia Medica (SIMM), have signed a memorandum of understanding aimed at accelerating the development and adoption of new cancer therapies. Overall, the collaboration...

NorwayNorway

18.09.2010

Oslo/Berlin – Algeta is cashing in on its lead product Alpharadin, a targeted alpha-radiopharmaceutical in clinical trials for treating bone metastases in cancer patients. Bayer Schering Pharma has agreed to pay the Norwegian...

NorwayNorway

11.07.2010

Lysaker – Norwegian biopharmaceutical company PCI Biotech Holding ASA has strengthened the company’s equity by a11m (NOK90m) through a share issue of 2.25 million shares with preemptive subscription rights for existing...

NorwayNorway

12.05.2010

Oslo – In Norway, a discussion has begun on how to continue to support biotechnology after the current National Programme for Research in Functional Genomics in Norway (FUGE) comes to a close in 2011. Efforts to draw up a...

Displaying results 11 to 20 out of 92

< Previous 11-20 Next >

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/1/article/apim-therapeutics-gets-new-funding.html

Whitepaper

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.15 SEK8.85%
  • HYBRIGENICS (F)0.94 EUR8.05%
  • IXICO (UK)31.50 GBP5.00%

FLOP

  • ARGEN-X (B)13.70 EUR-3.52%
  • VECTURA (UK)132.10 GBP-3.17%
  • SAREUM HOLDINGS (UK)0.72 GBP-2.70%

TOP

  • NORDIC NANOVECTOR (N)33.60 NOK34.9%
  • MOLMED (I)0.42 EUR27.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)6.15 SEK25.5%

FLOP

  • BIONOR PHARMA (N)0.42 NOK-22.2%
  • ACTIVE BIOTECH (S)12.20 SEK-18.4%
  • E-THERAPEUTICS (UK)11.50 GBP-14.1%

TOP

  • NICOX (F)10.31 EUR439.8%
  • SAREUM HOLDINGS (UK)0.72 GBP227.3%
  • GENMAB (DK)1095.00 DKK89.8%

FLOP

  • BB BIOTECH (D)44.55 EUR-82.4%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)96.20 GBP-71.7%

No liability assumed, Date: 31.08.2016

Events

All Events

Partner-Events